New diagnostic tools in male LUTS

Poster Session 09

  • Location:
    Room 14a (ICM, Level 1)
  • Chairs:
     M. Oelke, Hannover (DE)
     A. Tubaro, Rome (IT)
  • Aims and objectives of this session

    New diagnostic tools are being developed to allow us better screening and patient selection. These tools are being scrutinized in this session.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
Lower urinary tract symptoms, depression and adverse life events: Data from the European Male Ageing Study

By: Cocci A.1, Gacci M.1, Drake M.2, Castellini G.3, Ricca V.4, Forti G.4, Wu F.5, Maggi M.3

Institutes: 1University of Florence, Dept. of Urology, Florence, Italy, 2University of Bristol, Dept. of Urology, Bristol, United Kingdom, 3Sexual Medicine and Andrology Unit, Dept. of Experimental, Clinical and Biomedical Sciences, Florence, Italy, 4Psychiatric Unit, University of Florence, Dept. of Neuropsychiatric Sciences, Florence, Italy, 5Andrology Research Unit, Endocrinology and Diabetes Research Group, Institute of Human Development, Manchester, United Kingdom

Correlation between uroflowmetry and a new visual pictogram in patients with lower urinary tract symptoms: Analogical uroflowmetry (ANUF)

By: Rogel R., Lorenzo L., Avargues A., Lujan S., Broseta E., Boronat F.

Institutes: Hospital Universitari I Politècnic La Fe, Dept. of Urology, Valencia, Spain

A prostate cancer risk polymorphism (rs12500426) of the PDLIM5 gene is a strong determinant of age related benign prostate hypertrophy

By: Audouin M.1, Barkatz J.1, Cox D.8, Roupret M.2, Cormier L.3, Valeri A.4, Azzouzi A-R.5, Ondet V.6, Gaffory C.7, Cancel-Tassin G.7, Cussenot O.1

Institutes: 1Assistance Publique-Hopitaux De Paris, Tenon Hospital, Dept. of Urology, Paris, France, 2Assistance Publique-Hopitaux De Paris, Pitie-Salpetriere Hospital, Dept. of Urology, Paris, France, 3CHU Dijon, Dept. of Urology, Dijon, France, 4CHU Brest, Dept. of Urology, Brest, France, 5CHU Angers, Dept. of Urology, Angers, France, 6UPMC Univ Paris 06, GRC N°5 ONCOTYPE-URO, Paris, France, 7CeRePP, GRC N°5 ONCOTYPE-URO, Paris, France, 8INSERM, U1052, Lyon, France

Developing a clinical nomogram for detection of bladder outlet obstruction in non-neurogenic male patients with overactive bladder symptoms

By: Chen W.J., Fan Y.H., Lin A.T.L., Chen K.K.

Institutes: Taipei Veterans General Hospital, Dept. of Urology, Taipei City, Taiwan

Methylation of CpG islands in promoter of type 2 5-α reductase and implications of finasteride resistance for BPH therapy

By: Jin S., Fan D., Liu Z., Sun J., Xing N., Niu Y.

Institutes: Beijing Chao-Yang Hospital, Dept. of Urology, Beijing, China

Serum vitamin D level in benign prostatic hyperplasia and hypogonadism has different correlations according to metabolic status

By: Park M.G.1, Dae Yeon C.1, Jeong Kyun Y.1, Jeong Woo L.2, Sung Yong C.3, Min Chul C.3

Institutes: 1Inje University, Seoul Paik Hospital, Dept. of Urology, Seoul, South Korea, 2Dongguk University, Dept. of Urology, Seoul, South Korea, 3Seoul University, Dept. of Urology, Seoul, South Korea

Prospective evaluation of quality of information provided to patients before a transurethral resection of the prostate

By: Dominique I.1, Meyer V.2, Terrier J-E.1, Badet L.2, Paparel P.1, Ruffion A.1, Champetier D.1

Institutes: 1CHU Lyon Sud, Dept. of Urology, Rhones Alpes, Pierre Benite, France, 2CHU Edouard Herriot, Dept. of Urology, Rhones Alpes, Lyon, France

Impact of treatment with statin on prostate volume and lower urinary tract symptoms: 3-Year follow-up

By: Han J-Y., Jeong S.C., Lee S.S., Park S-W., Chung M.K.

Institutes: Pusan National University Hospital, Dept. of Urology, Yangsan, South Korea

Impairment of autophagy in prostatic inflammation

By: Vecchione A.1, De Nunzio C.2, Cirombella R.3, Lombardo R.4, Stoppacciaro A.3, Tubaro A.4

Institutes: 1Sant’ Andrea Hospital – Sapienza University , Dept. of Molecular Pathology, Rome, Italy, 2Sant’ Andrea Hospital – Sapienza , Dept. of Urology, Rome, Italy, 3Sant’ Andrea Hospital ‘la Sapienza’, Dept. of Molecular Pathology, Rome, Italy, 4Sant’ Andrea Hospital ‘la Sapienza’, Dept. of Urology, Rome, Italy

Intravesical prostatic protrusion can predict postoperative outcomes in patients with benign prostatic hyperplasia who undergo trans urethral resection of prostate (TURP)

By: Nur Budaya T.1, Daryanto B.2, Soetojo S.1

Institutes: 1Dr. Soetomo Hospital, Faculty of Medicine Airlangga University, Dept. of Urology, Surabaya, Indonesia, 2Dr. Saiful Anwar Hospital, Faculty of Medicine Brawijaya University, Dept. of Urology, Malang, Indonesia

The relationship between body mass index and benign prostate hyperplasia in large scale community based cohort

By: Choi S.M., Yoon S., Seo D.H., Jeh S.U., Kam S.C., Hwa J.S., Chung K.H., Hyun J.S.

Institutes: Gyeongsang National Unversity Hospital, Dept. of Urology, Jinju, South Korea

A preoperative nomogram to predict functional outcomes of Greenlight® XPS 180 W photoselective vaporization of the prostate

By: Peyronnet B.1, Hupertan V.2, Pradère B.3, Phé V.4, Zorn K.5, Rouprêt M.4, Misrai V.6

Institutes: 1CHU Rennes, Dept. of Urology, Rennes, France, 2Bichat Hospital, Dept. of Urology, Paris, France, 3CHU Tours, Dept. of Urology, Tours, France, 4Pitié Salpétrière Hospital, Dept. of Urology, Paris, France, 5McGill University, Dept. of Urology, Montreal, France, 6Clinique Pasteur, Dept. of Urology, Toulouse, France